Any current/future new fundraising through debt or equity?

No explicit mention of new fundraising through debt or equity in the transcript. The company incurred capex of INR 52 crores during Q1 FY25, mainly funded through internal accruals and partly through term loans. Anticipated total capex for FY25 is INR 200 crores, expected to be funded mainly through internal accruals and partly through term loans. No indication of fresh equity issuance or external debt raising plans beyond existing term loans mentioned for capex. Management did not highlight any upcoming fundraise for expansion or other purposes during the call.

Any current/future capex/capital investment/strategic investment?

INR 52 crores capex incurred in Q1 FY'25 for capacity expansion, backward integration, and new product launches in formulation. Total capex guidance for FY'25 is INR 200 crores, funded through internal accruals and partly through term loans. Two Greenfield projects nearing completion: one in Saykha (specialty chemicals and intermediates) expected by end Q2 FY'25; another minor component related to salicylic acid plot development. Brownfield expansions underway: Baddi facility formulation capacity to increase by 15-20% next quarter and potentially double in 12-15 months. Ongoing R&D on formulat

Future growth expectations in sales/revenue/volumes?

The company aims to achieve over INR 4,000 crores in revenue within the next 3-4 years, based on current prices and volume growth. API volume growth was flat in H1 FY'25 but expected to rebound to mid-teens percentage growth in H2 FY'25. Specialty Chemicals segment is projected to grow about 50% year-on-year in H2 FY'25 as new capacities come online. Formulation export business is growing due to new product launches and market expansions, with international business expected to offset domestic declines, supporting double-digit growth in formulations. Oncology formulations are expected

Future growth expectations in earnings/operating earnings/profits/EPS?

Aarti Drugs aims to achieve revenues upwards of INR 4,000 crores in the next 3-4 years (FY'27 target) based on volume growth and current pricing. Long-term EBITDA margins are targeted between 14% to 15%. Volume growth is expected to recover in H2 FY'25, with mid-teens growth for API business anticipated in the second half. Specialty Chemicals segment is expected to see ~50% year-on-year growth in H2 FY'25 as new capacities come online. Formulation exports are increasing with new product launches and new markets, offsetting domestic shifts; oncology formulations expected to start contributing s

Current/ Expected Orderbook/ Pending Orders?

The export orders have a pending order book of approximately 2.5 to 3 months. Export orders executed in March quarter were based on orders from December quarter when prices were higher. The June quarter orders executed were placed in March quarter when prices had fallen, leading to observed price decline in exports. Domestic order book is less than 1 month, showing quicker price reflection. Export demand remained subdued in Q1 and Q2 FY25 with expectations of improvement from Q3 onwards.

IN US

Sale is live|00:00:00left today

Aarti Drugs LtdQ2 FY24Pharmaceuticals & Biotechnology

Aarti Drugs Ltd Q2 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹371P/E: 17.2Market Cap: ₹3.4K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 2

Fundraise

Yes

Order

Capex

Yes

2 of 5 growth signals are positive.

Full analysis

Revenue guidance

Category 3

→The company aims to achieve over INR 4,000 crores in revenue within the next 3-4 years, based on current prices and volume growth.
→API volume growth was flat in H1 FY'25 but expected to rebound to mid-teens percentage growth in H2 FY'25.
→Specialty Chemicals segment is projected to grow about 50% year-on-year in H2 FY'25 as new capacities come online.
→Formulation export business is growing due to new product launches and market expansions, with international business expected to offset domestic declines, supporting double-digit growth in formulations.
→Oncology formulations are expected to begin contributing initial sales from FY'26 with major contributions from FY'27.
→Continuous increase in capacity, including expansions in Baddi and Saykha, will support growth.
→Margins expected to improve to 14-15% EBITDA long-term with better operating leverage and backward integration.

Margin guidance

Category 2

→Aarti Drugs aims to achieve revenues upwards of INR 4,000 crores in the next 3-4 years (FY'27 target) based on volume growth and current pricing.
→Long-term EBITDA margins are targeted between 14% to 15%.
→Volume growth is expected to recover in H2 FY'25, with mid-teens growth for API business anticipated in the second half.
→Specialty Chemicals segment is expected to see ~50% year-on-year growth in H2 FY'25 as new capacities come online.
→Formulation exports are increasing with new product launches and new markets, offsetting domestic shifts; oncology formulations expected to start contributing sales from FY'26.
→Capex of INR 200 crores planned for FY'25, focused on capacity expansion, backward integration, and new product launches, which will support margin improvement.
→Operating leverage and improved capacity utilization from new Greenfield projects expected to boost margins and profits in the second half of FY'25 and beyond.

3 more insights locked — sign up free to unlock

Fundraise plans

Yes

→No explicit mention of new fundraising through debt or equity in the transcript.
→The company incurred capex of INR 52 crores during Q1 FY25, mainly funded through internal accruals and partly through term loans.
→Anticipated total capex for FY25 is INR 200 crores, expected to be funded mainly through internal accruals and partly through term loans.
→No indication of fresh equity issuance or external debt raising plans beyond existing term loans mentioned for capex.
→Management did not highlight any upcoming fundraise for expansion or other purposes during the call.

Order book

→The export orders have a pending order book of approximately 2.5 to 3 months.
→Export orders executed in March quarter were based on orders from December quarter when prices were higher.
→The June quarter orders executed were placed in March quarter when prices had fallen, leading to observed price decline in exports.
→Domestic order book is less than 1 month, showing quicker price reflection.
→Export demand remained subdued in Q1 and Q2 FY25 with expectations of improvement from Q3 onwards.

Capex plans

Yes

→INR 52 crores capex incurred in Q1 FY'25 for capacity expansion, backward integration, and new product launches in formulation.
→Total capex guidance for FY'25 is INR 200 crores, funded through internal accruals and partly through term loans.
→Two Greenfield projects nearing completion: one in Saykha (specialty chemicals and intermediates) expected by end Q2 FY'25; another minor component related to salicylic acid plot development.
→Brownfield expansions underway: Baddi facility formulation capacity to increase by 15-20% next quarter and potentially double in 12-15 months.
→Ongoing R&D on formulation side focusing on new product development (oncology, cardiac, diabetic) for launches in next 2-3 years.
→Saykha Greenfield project capex mostly complete; minor residual capex expected this year.
→Metformin capacity expansion planned from current 1,400-1,500 tons/month to 1,700-1,800 tons/month, pending environmental approvals.

How does Aarti Drugs Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Aarti Drugs Ltd

Rev 3Mar 2

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Aarti Drugs Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio